iCAP-BI-28-KanR
(Plasmid
#203532)
-
PurposeRepCap for AAV production
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 203532 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backboneiCAP-KanR
-
Vector typeMammalian Expression, AAV
Growth in Bacteria
-
Bacterial Resistance(s)Kanamycin, 50 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)NEB Stable
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameAAV-BI28 Cap
-
SpeciesSynthetic
Cloning Information
- Cloning method Unknown
Resource Information
-
Supplemental Documents
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
iCAP-BI-28-KanR was a gift from Ben Deverman (Addgene plasmid # 203532 ; http://n2t.net/addgene:203532 ; RRID:Addgene_203532) -
For your References section:
Targeting AAV vectors to the central nervous system by engineering capsid-receptor interactions that enable crossing of the blood-brain barrier. Huang Q, Chen AT, Chan KY, Sorensen H, Barry AJ, Azari B, Zheng Q, Beddow T, Zhao B, Tobey IG, Moncada-Reid C, Eid FE, Walkey CJ, Ljungberg MC, Lagor WR, Heaney JD, Chan YA, Deverman BE. PLoS Biol. 2023 Jul 19;21(7):e3002112. doi: 10.1371/journal.pbio.3002112. eCollection 2023 Jul. 10.1371/journal.pbio.3002112 PubMed 37467291